Skip to search formSkip to main contentSkip to account menu

B2036-PEG

Known as: B-2036 PEG 
National Institutes of Health

Related topics

Related topics

4 relations

Broader (4)

Growth HormoneHormone Receptorantagonists & inhibitorspegvisomant

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2015
2015
Pegvisomant treatment in patients with acromegaly in clinical practice: The French ACROSTUDY.
2003
2003
Regulation of growth-hormone-receptor gene expression by growth hormone and pegvisomant in human mesangial cells.
BACKGROUND Mice transgenic for growth hormone develop mesangial proliferation, glomerular hypertrophy, and progressive glomerular… 
Highly Cited
1999
Highly Cited
1999
The Human Growth Hormone Antagonist B2036 Does Not Interact with the Prolactin Receptor.
The human growth hormone (hGH) antagonist B2036 combines a single amino acid substitution impairing receptor binding site 2… 
1999
1999
The human growth hormone antagonist B2036 does not interact with the prolactin receptor.
The human growth hormone (hGH) antagonist B2036 combines a single amino acid substitution impairing receptor binding site 2… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)